BEVERLY, MA, Mar 31, 2014 (Marketwired via COMTEX) -- Cellceutix Corporation (otcqb:CTIX) (the "Company"), ... is pleased to provide shareholders an update on the status of the Company's clinical trial of its novel antibiotic Brilacidin as a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). One month into the study, the trial has completed enrollment of approximately 20 percent of the total patients scheduled in the protocol.
The trial compares three different dosing regimens of Brilacidin, two single-dose regimens and one 3-day regimen, to a standard 7-day regimen of daptomycin, a drug marketed in the United States by Cubist Pharmaceuticals under the brand name Cubicin.
"The shortest dosing regimen of any antibiotic treatment for ABSSSI approved by the U.S. Food and Drug Administration is seven days," commented Leo Ehrlich, Chief Executive Officer at Cellceutix. "We believe that among comparably priced drugs that are safe and effective, the shortest course regimen will take over the market. We are pleased that the trial of our one- and three-day Brilacidin treatment is on schedule to date and we anticipate enrollment to be 50 percent complete in another six weeks."
About Cellceutix: Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix is planning a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol is presently in a bioequivalence crossover clinical trial in Miami, FL. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's key antibiotic, Brilacidin, is in a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com .